Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Asthma and COPD drug granted EU marketing authorisation

The drug Aerivio Spiromax (fluticasone/salmeterol 500/50) has received EU marketing authorisation as a maintenance bronchodilator treatment for adult patients with severe asthma and chronic obstructive pulmonary disease (COPD), Teva Pharmaceutical Industries Ltd has announced.

The drug Aerivio Spiromax (fluticasone/salmeterol 500/50) has received EU marketing authorisation as a maintenance bronchodilator treatment for adult patients with severe asthma and chronic obstructive pulmonary disease (COPD), Teva Pharmaceutical Industries Ltd has announced.  Aerivio Spiromax contains a fixed dose combination of fluticasone propionate, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and salmeterol xinafoate, a long-acting beta-agonist, delivered via the Spiromax inhaler. The Spiromax inhaler has previously received a Medical Design Excellence Award that recognizes significant advances in medical product design. The inhaler is primed by opening the cover and a click confirms it is

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy